Human Osteoactivin/GPNMB Antibody

Catalog # Availability Size / Price Qty
Detection of Human Osteoactivin/GPNMB by Western Blot.
2 Images
Product Details
Citations (19)
Supplemental Products

Human Osteoactivin/GPNMB Antibody Summary

Species Reactivity
Detects human Osteoactivin in ELISAs and Western blots. In sandwich immunoassays, less than 2% cross-reactivity with recombinant mouse Osteoactivin is observed.
Polyclonal Goat IgG
Antigen Affinity-purified
Mouse myeloma cell line NS0-derived recombinant human Osteoactivin isoform b
Accession # NP_002501
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.


Recommended Concentration
Western Blot
0.5 µg/mL
See below
5-15 µg/mL
See below

Human Osteoactivin/GPNMB Sandwich Immunoassay

Recommended Concentration
ELISA Capture (Matched Antibody Pair)
0.2-0.8 µg/mL 

Use in combination with:

Detection Reagent: Human Osteoactivin/GPNMB Biotinylated Antibody (Catalog # BAF2550)

Standard: Recombinant Human Osteoactivin/GPNMB Fc Chimera Protein, CF (Catalog # 2550-AC)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Human Osteoactivin/GPNMB antibody by Western Blot. View Larger

Detection of Human Osteoactivin/GPNMB by Western Blot. Western blot shows lysates of U-118-MG human glioblastoma/astrocytoma cell line and T98G human glioblastoma cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human Osteoactivin/GPNMB Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2550) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). Specific bands were detected for Osteoactivin/GPNMB at approximately 95 and 120 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Immunohistochemistry Osteoactivin/GPNMB antibody in Human Liver by Immunohistochemistry (IHC-P). View Larger

Osteoactivin/GPNMB in Human Liver. Osteoactivin/GPNMB was detected in immersion fixed paraffin-embedded sections of human liver using Goat Anti-Human Osteoactivin/GPNMB Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2550) at 3 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to Kupffer cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Preparation and Storage

Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Size / Price
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Osteoactivin/GPNMB

Osteoactivin (also GPNMB and DC-HIL) is a variably glycosylated 75 - 125 kDa member of the NMB/pMEL-17 family of molecules. It is found in multiple subcellular sites, but is most often associated with the endosomal/lysosomal compartment (1-3). Human Osteoactivin is a 560 amino acid (aa) type I transmembrane protein. Its precursor contains a 21 aa signal sequence, a 465 aa luminal/extracellular domain, a 21 aa transmembrane segment and a 53 aa cytoplasmic tail (4, 5). The luminal region contains an N-terminal heparin-binding motif (aa 23-26), multiple glycosylation sites, an RGD motif (aa 64-66) and an 88 aa PKD domain (aa 240-327). The intracellular tail has an ITAM (Y-x-x-I) and lysosomal targeting (L-L) motif (4, 5). The extracellular/luminal region shares 74% and 77% aa identity with the equivalent regions in mouse and canine, respectively. Multiple isoforms would appear to exist. There is one alternate splice form known that shows a 12 aa insert between aa 339-340 (6). An addtional 206 aa isoform shows a mutation at position # 181 that results in a 26 aa substitution for the C-terminal 380 amino acids (7, 8). This has the potential to be soluble and may represent a counterpart to a secreted isoform of rat Osteoactivin (9). Cells known to express Osteoactivin include macrophages/Kupffer cells, fibroblasts, osteoblasts, myeloid dendritic cells, retinal pigment epithelial cells and melanocytes, plus fetal chondrocytes and stratum basale keratinocytes (3-5, 10-12). In mice, Osteoactivin is reported to bind to heparan sulfate-proteoglycan, possibly on the surface of endothelial cells and may also interact with integrins (13). It also appears to act as an inflammatory suppressor gene, as its expression downregulates the macrophage inflammatory response by inhibiting IL-6 and IL-12 p40 production (3).

  1. Bachner, D. et al. (2002) Gene Exp. Patterns 1:159.
  2. Safadi, F.F. et al. (2002) J. Cell. Biochem. 84:12.
  3. Ripoll, V.M. et al. (2007) J. Immunol. 178:6557. 
  4. Owen, T.A. et al. (2003) Crit. Rev. Eukaryot. Gene Expr. 13:205. 
  5. Weterman, M.A.J. et al. (1995) Int. J. Cancer 60:73. 
  6. Kuan, C-T. et al. (2006) Clin. Cancer Res. 12:1970. 
  7. Lennerz, V. et al. (2005) Proc. Natl. Acad. Sci. USA 102:16013.
  8. Genbank Accession # AAH11595.
  9. Abdelmagid, S.M. et al. (2007) J. Cell. Physiol. 210:26.
  10. Haralanova-Ilieva, B. et al. (2005) J. Hepatol. 42:565.
  11. Ahn, J.H. et al. (2002) Blood 100:1742.
  12. Anderson, M.G. et al. (2002) Nat. Genet. 30:81.
  13. Shikano, S. et al. (2001) J. Biol. Chem. 276:8125.
Long Name
Glycoprotein Non-Metastatic Melanoma Protein B
Entrez Gene IDs
10457 (Human); 93695 (Mouse); 113955 (Rat); 102133517 (Cynomolgus Monkey)
Alternate Names
DC-HIL; glycoprotein (transmembrane) nmb; glycoprotein NMB; GPNMB; HGFIN; HGFINglycoprotein nmb-like protein; NMBosteoactivin; Osteoactivin; Transmembrane glycoprotein HGFIN; transmembrane glycoprotein NMB

Product Datasheets

You must select a language.


Citations for Human Osteoactivin/GPNMB Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

19 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. A novel missense mutation in the folliculin gene associated with the renal tumor-only phenotype of Birt-Hogg-Dub� syndrome
    Authors: T Sano, T Fukui, N Makita, K Shimizu, J Kono, K Masui, T Sato, T Goto, A Sawada, M Fujimoto, F Kojima, M Torishima, T Wada, M Furuya, O Ogawa, T Kobayashi, S Akamatsu
    Cancer genetics, 2022;266(0):28-32.
    Species: Human
    Sample Types: Tissue Homogenates
    Applications: Western Blot
  2. Classification of node-positive melanomas into prognostic subgroups using keratin, immune, and melanogenesis expression patterns
    Authors: D Netanely, S Leibou, R Parikh, N Stern, H Vaknine, R Brenner, S Amar, RH Factor, T Perluk, J Frand, E Nizri, D Hershkovit, V Zemser-Wer, C Levy, R Shamir
    Oncogene, 2021;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  3. Amyloidosis cutis dyschromica cases caused by GPNMB mutations with different inheritance patterns
    Authors: W Qin, H Wang, W Zhong, J Bai, J Qiao, Z Lin
    Journal of dermatological science, 2021;0(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  4. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations
    Authors: M Huang, E Modeste, E Dammer, P Merino, G Taylor, DM Duong, Q Deng, CJ Holler, M Gearing, D Dickson, NT Seyfried, T Kukar
    Acta Neuropathol Commun, 2020;8(1):163.
    Species: Human
    Sample Types: Protein
    Applications: Western Blot
  5. Clinical and Molecular Characterization of Microphthalmia-Associated Transcription Factor (MITF)-Related Renal Cell Carcinoma
    Authors: M Lang, CD Vocke, CJ Ricketts, AR Metwalli, MW Ball, LS Schmidt, WM Linehan
    Urology, 2020;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  6. GPNMB is expressed in human epidermal keratinocytes but disappears in the vitiligo lesional skin
    Authors: KB Biswas, A Takahashi, Y Mizutani, S Takayama, A Ishitsuka, L Yang, F Yang, A Iddamalgod, I Katayama, S Inoue
    Sci Rep, 2020;10(1):4930.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  7. Role of the kringle-like domain in glycoprotein NMB for its tumorigenic potential
    Authors: R Xie, Y Okita, Y Ichikawa, MA Fikry, KT Huynh Dam, STP Tran, M Kato
    Cancer Sci., 2019;110(7):2237-2246.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  8. TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease
    Authors: M Baba, M Furuya, T Motoshima, M Lang, S Funasaki, W Ma, HW Sun, H Hasumi, Y Huang, I Kato, T Kadomatsu, Y Satou, N Morris, BO Karim, L Ileva, JD Kalen, LA Wilan Kris, Y Hasumi, A Sugiyama, R Kurahashi, K Nishimoto, M Oyama, Y Nagashima, N Kuroda, K Araki, M Eto, M Yao, T Kamba, T Suda, Y Oike, LS Schmidt, WM Linehan
    Mol. Cancer Res., 2019;0(0):.
    Species: Human
    Sample Types: Paraffin-Embedded Tissue
    Applications: IHC
  9. GPNMB methylation: a new marker of potentially carcinogenic colon lesions
    Authors: H Ashktorab, H Rahi, M Nouraie, B Shokrani, E Lee, T Haydari, AO Laiyemo, P Siegel, H Brim
    BMC Cancer, 2018;18(1):1068.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  10. Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics
    Authors: X Ye, BT Luke, BR Wei, JA Kaczmarczy, J Loncarek, JE Dwyer, DJ Johann, RG Saul, DV Nissley, F McCormick, GR Whiteley, J Blonder
    Oncotarget, 2018;9(41):26431-26452.
    Species: Xenograft
    Sample Types: Whole Tissue
    Applications: IHC-P
  11. Glycoprotein nmb is exposed on the surface of dormant breast cancer cells and induces stem cell-like properties
    Authors: C Chen, Y Okita, Y Watanabe, F Abe, MA Fikry, Y Ichikawa, H Suzuki, A Shibuya, M Kato
    Cancer Res., 2018;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: FACS
  12. Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer
    Authors: JY Tajima, M Futamura, S Gaowa, R Mori, T Tanahashi, Y Tanaka, N Matsuhashi, T Takahashi, K Yamaguchi, T Miyazaki, K Yoshida
    J Cancer, 2018;9(2):358-366.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  13. Exploratory study on the effect of osteoactivin on muscle regeneration in a rat volumetric muscle loss model
    Authors: J Ma, AR Baker, A Calabro, KA Derwin
    PLoS ONE, 2017;12(4):e0175853.
    Species: N/A
    Sample Types: Gel Constructs
    Applications: IHC-Fr
  14. GPNMB ameliorates mutant TDP-43-induced motor neuron cell death
    Authors: Yuki Nagahara
    J. Neurosci. Res, 2016;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  15. Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease.
    Authors: Zigdon, Hila, Savidor, Alon, Levin, Yishai, Meshcheriakova, Anna, Schiffmann, Raphael, Futerman, Anthony
    PLoS ONE, 2015;10(3):e0120194.
    Species: Human
    Sample Types: CSF
    Applications: Western Blot
  16. GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity.
    Authors: Fiorentini C, Bodei S, Bedussi F, Fragni M, Bonini S, Simeone C, Zani D, Berruti A, Missale C, Memo M, Spano P, Sigala S
    Exp Cell Res, 2014;323(1):100-11.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  17. Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species.
    Authors: Patel-Chamberlin M, Wang Y, Satirapoj B
    Kidney Int., 2011;79(10):1138-48.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  18. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
    Authors: Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM
    Clin. Cancer Res., 2010;16(7):2147-56.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  19. Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
    Authors: Hong SB, Oh H, Valera VA, Baba M, Schmidt LS, Linehan WM
    PLoS ONE, 2010;5(12):e15793.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot


No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human Osteoactivin/GPNMB Antibody

There are currently no reviews for this product. Be the first to review Human Osteoactivin/GPNMB Antibody and earn rewards!

Have you used Human Osteoactivin/GPNMB Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review